Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell-Cell Interactions That Predict Immunotherapy Response.
Antoranz A, Van Herck Y, Bolognesi MM, Lynch SM, Rahman A, Gallagher WM, Boecxstaens V, Marine JC, Cattoretti G, van den Oord JJ, De Smet F, Bechter O, Bosisio FM. Antoranz A, et al. Among authors: bechter o. Cancer Res. 2022 Sep 16;82(18):3275-3290. doi: 10.1158/0008-5472.CAN-22-0363. Cancer Res. 2022. PMID: 35834277 Free PMC article.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
De Smedt J, Van Kelst S, Boecxstaens V, Stas M, Bogaerts K, Vanderschueren D, Aura C, Vandenberghe K, Lambrechts D, Wolter P, Bechter O, Nikkels A, Strobbe T, Emri G, Marasigan V, Garmyn M. De Smedt J, et al. Among authors: bechter o. BMC Cancer. 2017 Aug 23;17(1):562. doi: 10.1186/s12885-017-3538-4. BMC Cancer. 2017. PMID: 28835228 Free PMC article. Clinical Trial.
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Among authors: bechter o. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A, Thomas D, Vander Borght S, van den Oord JJ, Bechter O, Dewaele M, Rambow F, Marine JC, Wolter P. Rogiers A, et al. Among authors: bechter o. Br J Dermatol. 2019 Feb;180(2):421-422. doi: 10.1111/bjd.17250. Epub 2018 Nov 22. Br J Dermatol. 2019. PMID: 30248172 No abstract available.
Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.
Marasigan V, Güvenç C, Oord JJ, Stas M, Boecxstaens V, Bechter O, Wolter P, Lambrechts D, Garmyn M. Marasigan V, et al. Among authors: bechter o. Acta Derm Venereol. 2019 Jul 17;99(12):1154-1159. doi: 10.2340/00015555-3270. Online ahead of print. Acta Derm Venereol. 2019. PMID: 31314121 Free article.
94 results